Expired activity
Please go to the PowerPak homepage and select a course.

Nephrology Rounds: The Role of the Pharmacist in the Management of Anemia in Chronic Kidney Disease Patients

Provided by American Academy of CME, Inc.
American Academy of CME, Inc.

This educational activity is supported by an educational grant from Akebia Therapeutics.

Release date

April 30, 2020

Expiration date

April 30, 2021

Estimated time to complete activity

1.5 hours

Clinical Need

Anemia is common in patients with chronic kidney disease (CKD). Historically, treatment has consisted of oral or intravenous (IV) iron supplementation or the use of erythropoiesis stimulating agents (ESAs). Each of these approaches has its limitations and neither address the underlying cause of anemia. Advances in understanding the pathophysiological drivers of anemia in patients with CKD are informing the development of new approaches to correcting anemia in CKD, including stabilizing hypoxia inducible factor (HIF) by inhibiting prolyl hydroxylase (PH). Several HIF-stabilizers are currently being investigated and the role of these agents in treating anemia in patients with CKD is being shaped as data from clinical data are released.

As part of the interprofessional CKD healthcare team, pharmacists play a key role in comprehensive medication management as well as educating their colleagues about potential new treatments and implications for patient care.

Faculty Educators

Calvin J. Meaney, PharmD, BCPS
Clinical Associate Professor
University at Buffalo School of Pharmacy & Pharmaceutical Sciences

Target Audience

This activity has been developed for the pharmacist engaged in the care of patients with chronic kidney disease.

Educational Objectives

After attending this educational activity, learners should be better able to:

  1. Review the causes and underlying pathophysiology of anemia in patients with CKD
  2. Assess current options for treating anemia in patients with CKD
  3. Describe the role of hypoxia inducible factor (HIF) in CKD anemia and the rationale for developing therapy that targets prolyl hydroxylase (PH)
  4. Evaluate emerging data and clinical implications of HIF stabilization/PH inhibition as a strategy to address anemia in CKD
  5. Review the pharmacist role in patient care and management of therapy options

Accreditation and Credit Designation

Jointly Accredited ProviderIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


acpeThis activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-20-005-H01-P, Application

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are able to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Faculty Educator
Calvin J. Meaney, PharmD, BCPS
No relevant financial relationships with any commercial interests.

Planning Committee
John JD Juchniewicz, MCIS, CHCP, Edward Moylan, RPh, Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with any commercial interests.

Clinical Reviewer
Philip Coco, PharmD has no relevant financial relationships with any commercial interests.

This activity will review off-label or investigational information.


The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CPE credit for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately. For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only pharmacist learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

Hardware/Software Requirements

Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm


For any questions, please contact: CEServices@academycme.org


© 2020. This CPE-certified activity is held as copyrighted © by American Academy of CME, Inc. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).